Search Results - hsv

3 Results

Sort By:

Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility

Abstract: Griffithsin is a potent anti-viral protein with activity against HIV, HCV, Sars, HSV 1 & 2 and other viruses. It is active against HIV and HCV at picomolar concentrations. Griffithsin is moving into clinical trials as an anti-HIV microbicide. Based on the structure of griffithsin and the necessities of pharmaceutical product development...

Published: 7/16/2024 | Inventor(s): Barry O'Keefe, Kenneth Palmer, Tinoush Moulaei, Lisa Rohan, Joshua Fuqua, Lindsay Kramzer

Keywords(s): Anti-Viral, cnidarin, Griffithsin, HCV, HIV, HSV, SARS

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Stopping Neurogenesis in Transgenic Mice and Rat Models that Express the HSV-thymidine kinase Gene in Neuronal Precursor Cells

This invention relates to novel mouse and rat models that permit the temporal death of neuronal precursor cells at any time point. Other existing methods of decreasing neurogenesis are relatively non-specific (e.g., injecting glucocorticoids) or require expensive equipment (e.g., focal x-irradiation) These mice and rats are being used to inhibit adult...

Published: 7/25/2024 | Inventor(s): James Pickel, Heather Cameron

Keywords(s): Driving, Expression, GFAP, HSV, Kinase, Listed LPM Maddox as of 4/15/2015, Mice, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROMOTER, RATS, Thymidine, TRANSGENIC, VEXXXX, WIXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, Application > Research Materials

Use of Mono-Amine Oxidase Inhibitors to Prevent Herpes Virus Infections and Reactivation from Latency

Available for licensing are methods of using Monoamine Oxidase Inhibitors (MAOIs) to prevent alpha-herpesvirus lytic infections, such as those caused by Herpes simplex virus (HSV-1 or HSV-2) and Varicella zoster virus (VZV), and to possibly prevent the periodic reactivation of these viruses from latency. MAOIs have been historically used to treat depression,...

Published: 7/25/2024 | Inventor(s): Yu Liang, Thomas Kristie

Keywords(s): BBXXXX, CHEMISTRY, DB4BXX, DB4XXX, DBXXXX, DXXXXX, HERPES, HSV, HSV-1, hsv-2, Infection, INFECTIONS, Inhibitors, Latency, Mono-Amine, Mono-Anine, OXIDASE, Prevent, Reactivation, Reactiviation, Simpex, simplex, Variacella-zoster, Varicella Zoster, virus, VZV, ZOSTER

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease